Current status of short synthetic peptides as vaccines.

Current status of short synthetic peptides as vaccines. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Current status of short synthetic peptides as vaccines. Abstract Text:

Preventative medicine in the form of vaccination had a huge impact on human health in the 20th Century. Vaccines are now recognized as the most effective line of defence against infectious agents that cause disease and death, and in some cases vaccines have enabled complete eradication of disease from the globe (e.g. smallpox). Nevertheless there are still many human diseases (e.g. viral and parasitic infections, cancers) for which there are no effective vaccines. Current vaccines are mainly live and attenuated viruses or viral, bacterial or recombinant proteins and polypeptides. By virtue of their natural amino acid composition, polypeptides and proteins are relatively safe materials for vaccination, but they are expensive to manufacture making them inaccessible to the most vulnerable and needy human populations that cannot afford such medicines. This review will focus on shorter synthetic peptides that are cheaper to manufacture, conceivably even safer for human use because of increased specificity, but they also suffer from problems that have presumably resulted in their lack of progress in clinical trials. Since 1990, over 100 chemically synthesized short peptide vaccines have entered Phase I clinical trials, less than 20 have progressed into Phase II, but none have entered Phase III clinical trials. In this review we discuss reasons why vaccines based on short peptides may not have succeeded in the clinic, identify problems such as insufficient immunogenicity, structural/conformational instability, chemical instability due to degradation, and describe possible solutions to some of these problems that have been investigated in recent years.

Current status of short synthetic peptides as vaccines. Publishing Authors By Initials

For similar proteins: recombinant proteins: vaccines, synthetic research abstracts see: proteins: recombinant proteins: vaccines, synthetic research

PUBMED ID PMID:

MEDLINE DATE:

Current status of short synthetic peptides as vaccines. Journal Published:

PUBLICATION TYPE: Review

Journal: Medicinal chemistry (Sh?riqah (United Arab Emirate

VOLUME: 2

Page Numbers: 627-46

Journal Abbreviation:

ISSN: 1573-4064

DAY: 26

MONTH: Nov

YEAR: 2006

Current status of short synthetic peptides as vaccines. Information

Number of References: 237

LANGUAGE: eng

NlmUniqueID: 101240303

Current status of short synthetic peptides as vaccines. Keywords Mesh Terms:

KEYWORDS: Vaccines, Synthetic

MESH TERMS: immunology

Chemical & Substance for Abstract: Current status of short synthetic peptides as vaccines. Information

Substance Name: Vaccines, Synthetic

Registry Number: 0

Grant and Affiliation Information for Current status of short synthetic peptides as vaccines.

AFFILIATION: Centre for Drug Design and Development, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Med Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Current status of short synthetic peptides as vaccines Related Publications

• A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation.
• A refined agonist pharmacophore for protease activated receptor 2.
• Amyloid peptides and proteins in review.
• Cell phenotype as a target of drug therapy in chronic inflammatory diseases.
• Chronic gastritis as a source of gross hemorrhage; a report and discussion of four cases.
• Conformationally homogeneous cyclic tetrapeptides: useful new three-dimensional scaffolds.
• Consecutive cyclic pentapeptide modules form short alpha-helices that are very stable to water and denaturants.
• Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
• Current status of short synthetic peptides as vaccines.
• Cyclooligomerization of a helix-bearing template into macrocycles bearing multiple helices.
• EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency.
• Function, structure and therapeutic potential of complement C5a receptors.
• Hepta and octapeptide agonists of protease-activated receptor 2.
• Linkage Isomerism in the Binding of Pentapeptide Ac-His(Ala)3His-NH2 to (Ethylenediamine)Palladium(II): Effect of the Binding Mode on Peptide Conformation.
• New cysteine derivatives with antiproliferative activity on melanoma cells.
• New evidence of childhood leukaemias near nuclear power stations.
• Potent antimalarial activity of histone deacetylase inhibitor analogues.
• Profiling the enzymatic properties and inhibition of human complement factor B.
• Protease inhibitors in the clinic.
• Unexpected photolytic decomposition of alkyl azides under mild conditions.